Get the Stockscreener App
12.80
12.87%
-1.89
After Hours:
12.66
-0.14
-1.09%
Upstream Bio Inc stock is traded at $12.80, with a volume of 3.87M.
It is down -12.87% in the last 24 hours and down -59.57% over the past month.
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases.
See More
Previous Close:
$14.69
Open:
$14.86
24h Volume:
3.87M
Relative Volume:
5.15
Market Cap:
$691.69M
Revenue:
$2.22M
Net Income/Loss:
$-40.51M
P/E Ratio:
-9.9634
EPS:
-1.2847
Net Cash Flow:
$-46.53M
1W Performance:
-50.77%
1M Performance:
-59.57%
6M Performance:
-26.86%
1Y Performance:
+78.77%
1-Day Range:
$12.75
$14.86
1-Week Range:
$12.65
$28.57
52-Week Range:
$5.14
$33.68
Upstream Bio Inc Stock (UPB) Company Profile
Name
Upstream Bio Inc
Sector
Industry
Phone
781-208-2466
Address
890 WINTER STREET, SUITE 200, WALTHAM
Compare UPB vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
UPB
Upstream Bio Inc
|
12.80 | 793.83M | 2.22M | -40.51M | -46.53M | -1.2847 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Upstream Bio Inc Stock (UPB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-18-25 | Initiated | Mizuho | Outperform |
| Nov-18-25 | Initiated | Evercore ISI | Outperform |
| Oct-14-25 | Initiated | Truist | Buy |
| Nov-05-24 | Initiated | JP Morgan | Overweight |
| Nov-05-24 | Initiated | Piper Sandler | Overweight |
| Nov-05-24 | Initiated | TD Cowen | Buy |
| Nov-05-24 | Initiated | William Blair | Outperform |
View All
Upstream Bio Inc Stock (UPB) Latest News
Upstream Bio (NASDAQ:UPB) Trading Down 10.3%Time to Sell? - MarketBeat
Upstream Bio: Hold Rating As Verekitug Faces Competition Among Latest Asthma Data (UPB) - Seeking Alpha
Upstream Bio’s stock drops 47% on verekitug Phase II asthma data - Clinical Trials Arena
Upstream To Upgrade Verekitug To Phase III After Positive Asthma Results - Citeline News & Insights
Upstream Bio (NASDAQ:UPB) Shares Gap DownHere's Why - MarketBeat
VALIANT: Verekitug Reduces Average Annual Asthma Flare-Ups in Phase 2 Trial - HCPLive
Upstream Bio battered despite positive new verekitug data - The Pharma Letter
Upstream Bio Reports Positive Phase 2 Verekitug Asthma Results - TipRanks
UPB: Verekitug cut severe asthma exacerbations by up to 56% with durable efficacy and infrequent dosing - TradingView
Upstream Bio Faces New Strategic Challenges Amid Latest Developments - timothysykes.com
Upstream Bio stock tumbles after mixed Phase 2 asthma trial results - Investing.com Canada
Upstream Bio plunges as asthma drug misses 'home run' bar - TradingView
Upstream Bio posts mid-stage asthma trial win (UPB:NASDAQ) - Seeking Alpha
Upstream Bio shares plunge 20% premarket after co reports mid-stage asthma drug trial data - marketscreener.com
Upstream Bio reports positive top-line results from the phase 2 Valiant trial of Verekitug for the treatment of severe asthma - marketscreener.com
Upstream Bio Reports Positive Phase 2 Severe Asthma Data - TipRanks
Why Did UPB Stock Pop 20% In Pre-Market Today? - Mena FN
Upstream Bio, Inc. Reports Positive Phase 2 VALIANT Trial Results for Verekitug - TradingView
Upstream Bio Stock Pre-Market (+15%) : Positive Phase 2 Asthma Trial Data - Trefis
UPB: Verekitug showed robust efficacy and safety in severe asthma, advancing to Phase 3 trials - TradingView
Upstream Bio Reports Positive Top-Line Results From The Phase 2 Valiant Trial Of Verekitug For The Treatment Of Severe Asthma - TradingView
Upstream Bio Reports Positive Top-line Results from the - GlobeNewswire
Upstream Bio to report verekitug phase 2 trial results for severe asthma - Investing.com Canada
Upstream Bio To Present Phase 2 VALIANT Trial Results In Severe Asthma, Today - Nasdaq
Upstream Bio to report verekitug phase 2 trial results for severe asthma By Investing.com - Investing.com South Africa
Upstream Bio to reveal Phase 2 trial results for asthma drug - Traders Union
Upstream Bio to Host Webcast to Report Top-Line Results - GlobeNewswire
Upstream Bio (NASDAQ:UPB) Stock Price Up 9.4%Here's What Happened - MarketBeat
Severe Asthma Clinical Trial Analysis: In-Depth Analysis of 50+ - openPR.com
Upstream Bio, Inc. (NASDAQ:UPB) Receives $45.25 Consensus PT from Brokerages - Defense World
Upstream Bio, Inc. (NASDAQ:UPB) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Upstream Bio (NASDAQ:UPB) Stock Price Down 4.6%Should You Sell? - MarketBeat
Generate Biomedicines, Clinical-Stage Generative Biology Company Designing AI-Engineered Protein Therapeutics, Files for Nasdaq IPO - TradingView
Analysts Offer Insights on Healthcare Companies: Upstream Bio, Inc. (UPB) and BillionToOne, Inc. Class A (BLLN) - The Globe and Mail
Analyst Downgrade: Whats next for Upstream Bio Inc stockWeekly Stock Recap & Reliable Momentum Entry Alerts - baoquankhu1.vn
Stop Loss: What is the next catalyst for Upstream Bio IncChart Signals & Low Risk Entry Point Tips - baoquankhu1.vn
Analysts Are Bullish on These Healthcare Stocks: Guardant Health (GH), Regeneron (REGN) - The Globe and Mail
Upstream Bio, Inc. (UPB) Stock Analysis: Potential 49.64% Upside Amid Strong Buy Ratings - DirectorsTalk Interviews
Upstream Bio’s Verekitug Study: A Potential Game-Changer for Severe Asthma Treatment - MSN
Will Upstream Bio Inc. stock attract ESG investorsBlue Chip Stock Analysis & Get Ahead with Our Profit-Packed Picks - bollywoodhelpline.com
Aug Setups: What is the next catalyst for Upstream Bio IncEarnings Summary Report & Scalable Portfolio Growth Methods - baoquankhu1.vn
Aug Levels: Is CSGS forming bullish engulfing patterns2025 Earnings Impact & Consistent Profit Alerts - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: Upstream Bio, Inc. (UPB) and BioNano Genomics (BNGO) - The Globe and Mail
Sectors Review: Is Upstream Bio Inc a cyclical or defensive stockTake Profit & Community Verified Trade Alerts - baoquankhu1.vn
Why Upstream Bio (UPB) Is Up 12.2% After JPM Debut And VALINAT Hopes - simplywall.st
Can Upstream Bio Inc outperform in the next rallyWeekly Trading Summary & Long-Term Growth Stock Strategies - baoquankhu1.vn
Upstream Bio stock hits all-time high at 33.05 USD By Investing.com - Investing.com Nigeria
Aug Volume: Is Upstream Bio Inc a defensive stockMarket Risk Summary & Reliable Price Breakout Alerts - baoquankhu1.vn
Upstream Bio (NASDAQ:UPB) Reaches New 52-Week HighHere's What Happened - MarketBeat
Upstream Bio stock hits all-time high at 33.05 USD - Investing.com
US Market Recap: Can Upstream Bio Inc ride the EV wave2025 Price Action Summary & AI Forecasted Entry/Exit Points - baoquankhu1.vn
Upstream Bio Inc Stock (UPB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):